Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
Status:
RECRUITING
Trial end date:
2030-06-26
Target enrollment:
Participant gender:
Summary
This study will compare the effects of Quizartinib versus placebo in combination with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) negative acute myeloid leukemia (AML).
Phase:
PHASE3
Details
Lead Sponsor:
Daiichi Sankyo
Treatments:
Cytarabine Daunorubicin Drug Therapy Idarubicin quizartinib